View ValuationCellSeed 将来の成長Future 基準チェック /06現在、 CellSeedの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長39.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 24CellSeed Inc. to Report Q1, 2026 Results on May 13, 2026CellSeed Inc. announced that they will report Q1, 2026 results on May 13, 2026お知らせ • Feb 16CellSeed Inc., Annual General Meeting, Mar 25, 2026CellSeed Inc., Annual General Meeting, Mar 25, 2026.お知らせ • Dec 03CellSeed Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026CellSeed Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026お知らせ • Nov 20CellSeed Inc. announced that it expects to receive ¥3.44 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement by the Resolution of the Board of Directors to issue 86,000 25th Series of Stock Acquisition Rights at a price of ¥40 per stock acquisition right for gross proceeds of ¥3,440,000 on November 20, 2025. The transaction includes participation from Barclays Bank PLC. The Stock Acquisition Rights are convertible into 8,600,000 Ordinary Shares for gross proceeds of ¥3,268,000,000. The initial exercise price will be ¥380. On or after December 9, 2025, the exercise price will be revised on the effective date of each exercise request for the Stock Acquisition Rights to an amount equivalent to 97% of the closing price of the Company's common shares in regular trading on the Tokyo Stock Exchange on the trading day immediately preceding the revision date. If the revised exercise price based on this calculation falls below the minimum exercise price, the minimum exercise price will be the revised exercise price. The exercise period starts from from December 9, 2025 to December 8, 2027.New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).New Risk • Oct 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.5b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Market cap is less than US$100m (JP¥14.5b market cap, or US$99.1m).お知らせ • Sep 27CellSeed Inc. to Report Q3, 2025 Results on Nov 13, 2025CellSeed Inc. announced that they will report Q3, 2025 results on Nov 13, 2025お知らせ • Jun 17CellSeed Inc. to Report Q2, 2025 Results on Aug 13, 2025CellSeed Inc. announced that they will report Q2, 2025 results on Aug 13, 2025お知らせ • Apr 08CellSeed Inc. to Report Q1, 2025 Results on May 13, 2025CellSeed Inc. announced that they will report Q1, 2025 results on May 13, 2025New Risk • Mar 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (9.7% average weekly change).お知らせ • Feb 13CellSeed Inc., Annual General Meeting, Mar 25, 2025CellSeed Inc., Annual General Meeting, Mar 25, 2025.New Risk • Dec 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.3b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (JP¥15.3b market cap, or US$99.7m).お知らせ • Dec 03CellSeed Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025CellSeed Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025お知らせ • Oct 21CellSeed Inc. to Report Nine Months, 2024 Results on Nov 14, 2024CellSeed Inc. announced that they will report nine months, 2024 results on Nov 14, 2024お知らせ • Jun 22CellSeed Inc. to Report Q2, 2024 Results on Aug 13, 2024CellSeed Inc. announced that they will report Q2, 2024 results on Aug 13, 2024New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥8.82b market cap, or US$56.3m).お知らせ • Apr 26CellSeed Inc. to Report Q1, 2024 Results on May 13, 2024CellSeed Inc. announced that they will report Q1, 2024 results on May 13, 2024お知らせ • Feb 13CellSeed Inc., Annual General Meeting, Mar 26, 2024CellSeed Inc., Annual General Meeting, Mar 26, 2024.お知らせ • Feb 08MetaTech (AP) Inc. Files Lawsuit Against CellSeed IncMetaTech (AP) Inc. has filed a lawsuit in Japan to confirm the existence of the contractual relationship between CellSeed Inc. about Collaboration Agreement etc. Details of occurrence (including the matter under dispute): CellSeed law firm commissioned the Baker McKenzie to send a lawyer's letter on 2023/12/19. In the absence of specific evidence and solely relying on media reports, they unilaterally claimed that company breached the Collaboration Agreement and terminated various contracts signed by both parties. To protect own interests, company has engaged Japanese lawyers to file a lawsuit in the Tokyo District Court in Japan to confirm the existence of the contractual relationship.お知らせ • Jan 13CellSeed Inc. to Report Fiscal Year 2023 Results on Feb 13, 2024CellSeed Inc. announced that they will report fiscal year 2023 results on Feb 13, 2024お知らせ • Oct 24CellSeed Inc. to Report Nine Months, 2023 Results on Nov 14, 2023CellSeed Inc. announced that they will report nine months, 2023 results on Nov 14, 2023お知らせ • Jul 24CellSeed Inc. to Report First Half, 2023 Results on Aug 14, 2023CellSeed Inc. announced that they will report first half, 2023 results on Aug 14, 2023お知らせ • Jun 06CellSeed Inc. announced that it has received ¥2.001 million in funding from Barclays Bank PLC, Investment ArmOn June 5, 2023, CellSeed Inc. closed the transaction.お知らせ • May 17MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776).MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776) on May 15, 2023. Transfer execution date is June to late July 2023.お知らせ • May 16CellSeed Inc. announced that it expects to receive ¥2.001 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement of of 69,000 24th stock acquisition rights at ¥29 per warrant for gross proceeds of ¥2,001,000 on May 15, 2023. The transaction will involve participation from returning investor Barclays Bank PLC, Investment Arm. The warrants will be exercisable into 6,900,000 common shares of the company. The minimum exercise price of warrants is ¥178 per share. The warrants will be exercisable from allocation date to June 12, 2025. The company will issue securities through third-party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close between June 5, 2023 and June 12, 2023.Board Change • Apr 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Outside Director Toshio Yamaguchi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 15CellSeed Inc., Annual General Meeting, Mar 28, 2023CellSeed Inc., Annual General Meeting, Mar 28, 2023.お知らせ • Jan 24CellSeed Inc. to Report Fiscal Year 2022 Results on Feb 14, 2023CellSeed Inc. announced that they will report fiscal year 2022 results on Feb 14, 2023お知らせ • Oct 27CellSeed Inc. to Report Nine Months, 2022 Results on Nov 14, 2022CellSeed Inc. announced that they will report nine months, 2022 results on Nov 14, 2022お知らせ • May 03CellSeed Inc. to Report Q1, 2022 Results on May 12, 2022CellSeed Inc. announced that they will report Q1, 2022 results on May 12, 2022Reported Earnings • Apr 02Full year 2021 earnings released: JP¥53.14 loss per share (vs JP¥55.25 loss in FY 2020)Full year 2021 results: JP¥53.14 loss per share. Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020).Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥53.14 loss per share (up from JP¥55.25 loss in FY 2020). Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 41% per year.お知らせ • Feb 15CellSeed Inc., Annual General Meeting, Mar 25, 2022CellSeed Inc., Annual General Meeting, Mar 25, 2022.お知らせ • Jan 06CellSeed Inc. announced that it has received ¥1.144 million in funding from Barclays Bank PLC, Investment ArmOn January 5, 2022, CellSeed Inc. closed the transaction.お知らせ • Dec 21CellSeed Inc. announced that it expects to receive ¥1.144 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement of 44,000 22nd stock acquisition rights at ¥26 per warrant for gross proceeds of ¥1,144,000 on December 20, 2021. The transaction will involve participation from Barclays Bank PLC, Investment Arm. The allotment date for warrants is January 5, 2022. The warrants will be exercisable into 4,400,000 common shares of the company at an initial exercise price of ¥196 per share, revisable. The minimum exercise price of warrants is ¥98 per share. The warrants will be exercisable From January 6, 2022 to January 5, 2023. The company will issue securities through third-party allotment. The transaction has been approved by board of directors of the company.Reported Earnings • Nov 13Third quarter 2021 earnings released: JP¥12.24 loss per share (vs JP¥18.78 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥47.0m (up 88% from 3Q 2020). Net loss: JP¥217.0m (loss narrowed 20% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 18Second quarter 2021 earnings released: JP¥14.17 loss per share (vs JP¥11.41 loss in 2Q 2020)The company reported a mediocre second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: JP¥40.0m (up 48% from 2Q 2020). Net loss: JP¥240.0m (loss widened 52% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year and the company’s share price has also fallen by 37% per year.Reported Earnings • May 16First quarter 2021 earnings released: JP¥15.04 loss per share (vs JP¥13.69 loss in 1Q 2020)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥41.0m (up 32% from 1Q 2020). Net loss: JP¥246.0m (loss widened 35% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Feb 18New 90-day high: JP¥290The company is up 3.0% from its price of JP¥281 on 20 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.お知らせ • Feb 16CellSeed Inc., Annual General Meeting, Mar 26, 2021CellSeed Inc., Annual General Meeting, Mar 26, 2021.Reported Earnings • Feb 14Full year 2020 earnings released: JP¥55.25 loss per share (vs JP¥66.57 loss in FY 2019)The company reported a poor full year result with weaker revenues, weaker control over costs and no improvement to losses. Full year 2020 results: Revenue: JP¥199.0m (down 28% from FY 2019). Net loss: JP¥783.0m (flat on FY 2019). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Dec 28New 90-day low: JP¥225The company is down 35% from its price of JP¥348 on 29 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.Is New 90 Day High Low • Dec 09New 90-day low: JP¥264The company is down 22% from its price of JP¥339 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.分析記事 • Nov 17Is CellSeed (TYO:7776) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Nov 15Third quarter 2020 earnings released: JP¥18.78 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: JP¥25.0m (down 48% from 3Q 2019). Net loss: JP¥271.0m (loss widened 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 11New 90-day low: JP¥295The company is down 16% from its price of JP¥350 on 13 August 2020. The Japanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.お知らせ • Nov 10CellSeed Inc. to Report Fiscal Year 2020 Results on Feb 14, 2021CellSeed Inc. announced that they will report fiscal year 2020 results at 12:30 PM, GMT Standard Time on Feb 14, 2021Is New 90 Day High Low • Oct 15New 90-day low: JP¥319The company is down 14% from its price of JP¥372 on 17 July 2020. The Japanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 12% over the same period.お知らせ • Aug 07+ 1 more updateCellSeed Inc. announced that it has received ¥3.78 million in funding from Barclays Bank PLC, Investment ArmOn August 6, 2020, CellSeed Inc. (JASDAQ:7776) closed the transaction. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、CellSeed は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:7776 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2021161-914-908-817N/A9/30/2021244-875N/AN/AN/A6/30/2021222-929-816-800N/A3/31/2021209-847N/AN/AN/A12/31/2020199-783-710-700N/A9/30/2020148-836N/AN/AN/A6/30/2020171-803-788-779N/A3/31/2020189-812N/AN/AN/A12/31/2019275-782-590-577N/A9/30/2019693-332N/AN/AN/A6/30/2019841-149-270-262N/A3/31/20191,03287N/AN/AN/A12/31/20181,026129-307-306N/A9/30/2018586-388N/AN/AN/A6/30/2018406-617-540-537N/A3/31/2018184-843N/AN/AN/A12/31/201785-966-752-747N/A9/30/2017106-1,399N/AN/AN/A6/30/201798-1,357-896-783N/A3/31/2017105-1,419N/AN/AN/A12/31/2016100-1,414-1,195-852N/A9/30/2016190-775N/AN/AN/A6/30/2016192-685-1,214-738N/A3/31/2016182-582N/AN/AN/A12/31/2015193-535-919-675N/A9/30/201572-593N/AN/AN/A6/30/201581-586N/A-591N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 7776の予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 7776の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 7776の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 7776の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 7776の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 7776の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 11:23終値2026/06/11 00:00収益2021/12/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CellSeed Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.null nullInvestment Bridge Co., Ltd.Kyoichiro ShigemuraNomura Securities Co. Ltd.
お知らせ • Apr 24CellSeed Inc. to Report Q1, 2026 Results on May 13, 2026CellSeed Inc. announced that they will report Q1, 2026 results on May 13, 2026
お知らせ • Feb 16CellSeed Inc., Annual General Meeting, Mar 25, 2026CellSeed Inc., Annual General Meeting, Mar 25, 2026.
お知らせ • Dec 03CellSeed Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026CellSeed Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026
お知らせ • Nov 20CellSeed Inc. announced that it expects to receive ¥3.44 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement by the Resolution of the Board of Directors to issue 86,000 25th Series of Stock Acquisition Rights at a price of ¥40 per stock acquisition right for gross proceeds of ¥3,440,000 on November 20, 2025. The transaction includes participation from Barclays Bank PLC. The Stock Acquisition Rights are convertible into 8,600,000 Ordinary Shares for gross proceeds of ¥3,268,000,000. The initial exercise price will be ¥380. On or after December 9, 2025, the exercise price will be revised on the effective date of each exercise request for the Stock Acquisition Rights to an amount equivalent to 97% of the closing price of the Company's common shares in regular trading on the Tokyo Stock Exchange on the trading day immediately preceding the revision date. If the revised exercise price based on this calculation falls below the minimum exercise price, the minimum exercise price will be the revised exercise price. The exercise period starts from from December 9, 2025 to December 8, 2027.
New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).
New Risk • Oct 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.5b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Market cap is less than US$100m (JP¥14.5b market cap, or US$99.1m).
お知らせ • Sep 27CellSeed Inc. to Report Q3, 2025 Results on Nov 13, 2025CellSeed Inc. announced that they will report Q3, 2025 results on Nov 13, 2025
お知らせ • Jun 17CellSeed Inc. to Report Q2, 2025 Results on Aug 13, 2025CellSeed Inc. announced that they will report Q2, 2025 results on Aug 13, 2025
お知らせ • Apr 08CellSeed Inc. to Report Q1, 2025 Results on May 13, 2025CellSeed Inc. announced that they will report Q1, 2025 results on May 13, 2025
New Risk • Mar 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (9.7% average weekly change).
お知らせ • Feb 13CellSeed Inc., Annual General Meeting, Mar 25, 2025CellSeed Inc., Annual General Meeting, Mar 25, 2025.
New Risk • Dec 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.3b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (JP¥15.3b market cap, or US$99.7m).
お知らせ • Dec 03CellSeed Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025CellSeed Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025
お知らせ • Oct 21CellSeed Inc. to Report Nine Months, 2024 Results on Nov 14, 2024CellSeed Inc. announced that they will report nine months, 2024 results on Nov 14, 2024
お知らせ • Jun 22CellSeed Inc. to Report Q2, 2024 Results on Aug 13, 2024CellSeed Inc. announced that they will report Q2, 2024 results on Aug 13, 2024
New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥8.82b market cap, or US$56.3m).
お知らせ • Apr 26CellSeed Inc. to Report Q1, 2024 Results on May 13, 2024CellSeed Inc. announced that they will report Q1, 2024 results on May 13, 2024
お知らせ • Feb 13CellSeed Inc., Annual General Meeting, Mar 26, 2024CellSeed Inc., Annual General Meeting, Mar 26, 2024.
お知らせ • Feb 08MetaTech (AP) Inc. Files Lawsuit Against CellSeed IncMetaTech (AP) Inc. has filed a lawsuit in Japan to confirm the existence of the contractual relationship between CellSeed Inc. about Collaboration Agreement etc. Details of occurrence (including the matter under dispute): CellSeed law firm commissioned the Baker McKenzie to send a lawyer's letter on 2023/12/19. In the absence of specific evidence and solely relying on media reports, they unilaterally claimed that company breached the Collaboration Agreement and terminated various contracts signed by both parties. To protect own interests, company has engaged Japanese lawyers to file a lawsuit in the Tokyo District Court in Japan to confirm the existence of the contractual relationship.
お知らせ • Jan 13CellSeed Inc. to Report Fiscal Year 2023 Results on Feb 13, 2024CellSeed Inc. announced that they will report fiscal year 2023 results on Feb 13, 2024
お知らせ • Oct 24CellSeed Inc. to Report Nine Months, 2023 Results on Nov 14, 2023CellSeed Inc. announced that they will report nine months, 2023 results on Nov 14, 2023
お知らせ • Jul 24CellSeed Inc. to Report First Half, 2023 Results on Aug 14, 2023CellSeed Inc. announced that they will report first half, 2023 results on Aug 14, 2023
お知らせ • Jun 06CellSeed Inc. announced that it has received ¥2.001 million in funding from Barclays Bank PLC, Investment ArmOn June 5, 2023, CellSeed Inc. closed the transaction.
お知らせ • May 17MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776).MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776) on May 15, 2023. Transfer execution date is June to late July 2023.
お知らせ • May 16CellSeed Inc. announced that it expects to receive ¥2.001 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement of of 69,000 24th stock acquisition rights at ¥29 per warrant for gross proceeds of ¥2,001,000 on May 15, 2023. The transaction will involve participation from returning investor Barclays Bank PLC, Investment Arm. The warrants will be exercisable into 6,900,000 common shares of the company. The minimum exercise price of warrants is ¥178 per share. The warrants will be exercisable from allocation date to June 12, 2025. The company will issue securities through third-party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close between June 5, 2023 and June 12, 2023.
Board Change • Apr 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Outside Director Toshio Yamaguchi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 15CellSeed Inc., Annual General Meeting, Mar 28, 2023CellSeed Inc., Annual General Meeting, Mar 28, 2023.
お知らせ • Jan 24CellSeed Inc. to Report Fiscal Year 2022 Results on Feb 14, 2023CellSeed Inc. announced that they will report fiscal year 2022 results on Feb 14, 2023
お知らせ • Oct 27CellSeed Inc. to Report Nine Months, 2022 Results on Nov 14, 2022CellSeed Inc. announced that they will report nine months, 2022 results on Nov 14, 2022
お知らせ • May 03CellSeed Inc. to Report Q1, 2022 Results on May 12, 2022CellSeed Inc. announced that they will report Q1, 2022 results on May 12, 2022
Reported Earnings • Apr 02Full year 2021 earnings released: JP¥53.14 loss per share (vs JP¥55.25 loss in FY 2020)Full year 2021 results: JP¥53.14 loss per share. Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020).
Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥53.14 loss per share (up from JP¥55.25 loss in FY 2020). Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 41% per year.
お知らせ • Feb 15CellSeed Inc., Annual General Meeting, Mar 25, 2022CellSeed Inc., Annual General Meeting, Mar 25, 2022.
お知らせ • Jan 06CellSeed Inc. announced that it has received ¥1.144 million in funding from Barclays Bank PLC, Investment ArmOn January 5, 2022, CellSeed Inc. closed the transaction.
お知らせ • Dec 21CellSeed Inc. announced that it expects to receive ¥1.144 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement of 44,000 22nd stock acquisition rights at ¥26 per warrant for gross proceeds of ¥1,144,000 on December 20, 2021. The transaction will involve participation from Barclays Bank PLC, Investment Arm. The allotment date for warrants is January 5, 2022. The warrants will be exercisable into 4,400,000 common shares of the company at an initial exercise price of ¥196 per share, revisable. The minimum exercise price of warrants is ¥98 per share. The warrants will be exercisable From January 6, 2022 to January 5, 2023. The company will issue securities through third-party allotment. The transaction has been approved by board of directors of the company.
Reported Earnings • Nov 13Third quarter 2021 earnings released: JP¥12.24 loss per share (vs JP¥18.78 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥47.0m (up 88% from 3Q 2020). Net loss: JP¥217.0m (loss narrowed 20% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 18Second quarter 2021 earnings released: JP¥14.17 loss per share (vs JP¥11.41 loss in 2Q 2020)The company reported a mediocre second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: JP¥40.0m (up 48% from 2Q 2020). Net loss: JP¥240.0m (loss widened 52% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year and the company’s share price has also fallen by 37% per year.
Reported Earnings • May 16First quarter 2021 earnings released: JP¥15.04 loss per share (vs JP¥13.69 loss in 1Q 2020)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥41.0m (up 32% from 1Q 2020). Net loss: JP¥246.0m (loss widened 35% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Feb 18New 90-day high: JP¥290The company is up 3.0% from its price of JP¥281 on 20 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
お知らせ • Feb 16CellSeed Inc., Annual General Meeting, Mar 26, 2021CellSeed Inc., Annual General Meeting, Mar 26, 2021.
Reported Earnings • Feb 14Full year 2020 earnings released: JP¥55.25 loss per share (vs JP¥66.57 loss in FY 2019)The company reported a poor full year result with weaker revenues, weaker control over costs and no improvement to losses. Full year 2020 results: Revenue: JP¥199.0m (down 28% from FY 2019). Net loss: JP¥783.0m (flat on FY 2019). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Dec 28New 90-day low: JP¥225The company is down 35% from its price of JP¥348 on 29 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Dec 09New 90-day low: JP¥264The company is down 22% from its price of JP¥339 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
分析記事 • Nov 17Is CellSeed (TYO:7776) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Nov 15Third quarter 2020 earnings released: JP¥18.78 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: JP¥25.0m (down 48% from 3Q 2019). Net loss: JP¥271.0m (loss widened 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 11New 90-day low: JP¥295The company is down 16% from its price of JP¥350 on 13 August 2020. The Japanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.
お知らせ • Nov 10CellSeed Inc. to Report Fiscal Year 2020 Results on Feb 14, 2021CellSeed Inc. announced that they will report fiscal year 2020 results at 12:30 PM, GMT Standard Time on Feb 14, 2021
Is New 90 Day High Low • Oct 15New 90-day low: JP¥319The company is down 14% from its price of JP¥372 on 17 July 2020. The Japanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 12% over the same period.
お知らせ • Aug 07+ 1 more updateCellSeed Inc. announced that it has received ¥3.78 million in funding from Barclays Bank PLC, Investment ArmOn August 6, 2020, CellSeed Inc. (JASDAQ:7776) closed the transaction.